Furthermore, a trend was shown for patients with SSc SLCO1B1 rs4149056 variant carriers treated with MTX to less frequently experience high RVSP (p = 0.04, padj = 0.07). This evidence concerns the gene SLCO1B1 and systemic sclerosis.